Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Stock Has Consensus Target Price of $9.40

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have earned an average rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.40.

Several research firms have recently weighed in on TVRD. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 1st. Chardan Capital began coverage on shares of Tvardi Therapeutics in a research report on Tuesday, October 20th. They set a “buy” rating on the stock. BTIG Research decreased their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Finally, Lucid Cap Mkts raised Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th.

Institutional Trading of Tvardi Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics in the 2nd quarter worth about $34,000. Susquehanna International Group LLP acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $63,000. Finally, BlackRock Inc. bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at about $181,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Stock Down 5.0%

Shares of TVRD opened at $1.34 on Friday. The business’s 50 day moving average is $1.26 and its two-hundred day moving average is $2.63. Tvardi Therapeutics has a 52-week low of $0.77 and a 52-week high of $5.69. The firm has a market cap of $17.87 million, a price-to-earnings ratio of -0.48 and a beta of 0.37.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, equities analysts expect that Tvardi Therapeutics will post -2.23 earnings per share for the current fiscal year.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development. The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.